{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:59:02Z","timestamp":1788969542587,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,29]]},"DOI":"10.7759\/cureus.59285","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T14:47:00Z","timestamp":1714402020000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of Macrophage Activation Syndrome With Elderly Onset Still\u2019s Disease Under Tocilizumab Treatment"],"prefix":"10.7759","author":[{"given":"Yuhei","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3546-8","article-title":"Epidemiological study of adult-onset Still's disease using a Japanese administrative database","volume":"36","author":"Sakata N","year":"2016","unstructured":"Sakata N, Shimizu S, Hirano F, Fushimi K. Epidemiological study of adult-onset Still's disease using a Japanese administrative database. Rheumatol Int. 2016, 36:1399-405. 10.1007\/s00296-016-3546-8","journal-title":"Rheumatol Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10932-3","article-title":"Clinical characteristics and treatment of elderly onset adult-onset Still's disease","volume":"12","author":"Kishida D","year":"2022","unstructured":"Kishida D, Ichikawa T, Takamatsu R, et al.. Clinical characteristics and treatment of elderly onset adult-onset Still's disease. Sci Rep. 2022, 12:6787. 10.1038\/s41598-022-10932-3","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1829340","article-title":"Clinical features of elderly-onset adult-onset Still\u2019s disease","volume":"31","author":"Maruyama A","year":"2021","unstructured":"Maruyama A, Kokuzawa A, Yamauchi Y, et al.. Clinical features of elderly-onset adult-onset Still\u2019s disease. Mod Rheumatol. 2021, 31:862-8. 10.1080\/14397595.2020.1829340","journal-title":"Mod Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029354","article-title":"Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: a case report","volume":"101","author":"Horiuchi Y","year":"2022","unstructured":"Horiuchi Y, Hashimoto K, Horikoshi H, et al.. Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: a case report. Medicine (Baltimore). 2022, 101:e29354. 10.1097\/MD.0000000000029354","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1899565","article-title":"Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: a single-center observational study","volume":"32","author":"Yamabe T","year":"2022","unstructured":"Yamabe T, Ohmura SI, Uehara K, Naniwa T. Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: a single-center observational study. Mod Rheumatol. 2022, 32:169-76. 10.1080\/14397595.2021.1899565","journal-title":"Mod Rheumatol"},{"key":"ref6","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi M","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al.. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992, 19:424-30.","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/128623","article-title":"An unusual case of adult-onset Still\u2019s disease with hemophagocytic syndrome, necrotic leukoencephalopathy and disseminated intravascular coagulation","volume":"2014","author":"Namas R","year":"2014","unstructured":"Namas R, Nannapaneni N, Venkatram M, Altinok G, Levine M, Dhar JP. An unusual case of adult-onset Still\u2019s disease with hemophagocytic syndrome, necrotic leukoencephalopathy and disseminated intravascular coagulation. Case Rep Rheumatol. 2014, 2014:128623. 10.1155\/2014\/128623","journal-title":"Case Rep Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.255.195","article-title":"Clinical characteristics of Japanese patients with elderly-onset adult-onset Still\u2019s disease","volume":"255","author":"Suzuki E","year":"2021","unstructured":"Suzuki E, Temmoku J, Fujita Y, Yashiro-Furuya M, Asano T, Kanno T, Migita K. Clinical characteristics of Japanese patients with elderly-onset adult-onset Still\u2019s disease. Tohoku J Exp Med. 2021, 255:195-202. 10.1620\/tjem.255.195","journal-title":"Tohoku J Exp Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0348-9","article-title":"Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome","volume":"21","author":"Kobayashi M","year":"2011","unstructured":"Kobayashi M, Takahashi Y, Yamashita H, et al.. Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011, 21:92-6. 10.1007\/s10165-010-0348-9","journal-title":"Mod Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.899178","article-title":"Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease","volume":"26","author":"Bannai E","year":"2016","unstructured":"Bannai E, Yamashita H, Kaneko S, et al.. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol. 2016, 26:297-301. 10.3109\/14397595.2014.899178","journal-title":"Mod Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1221875","article-title":"Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still's disease","volume":"27","author":"Tsuchida Y","year":"2017","unstructured":"Tsuchida Y, Sumitomo S, Shoda H, Kubo K, Fujio K, Yamamoto K. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still's disease. Mod Rheumatol. 2017, 27:556-7. 10.1080\/14397595.2016.1221875","journal-title":"Mod Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease","volume":"7","author":"Li T","year":"2017","unstructured":"Li T, Gu L, Wang X, Guo L, Shi H, Yang C, Chen S. A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease. Sci Rep. 2017, 7:13477. 10.1038\/s41598-017-13639-y","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko Y","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, et al.. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018, 77:1720-9. 10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/226398-a-case-of-macrophage-activation-syndrome-with-elderly-onset-stills-disease-under-tocilizumab-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T14:47:05Z","timestamp":1714402025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/226398-a-case-of-macrophage-activation-syndrome-with-elderly-onset-stills-disease-under-tocilizumab-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.59285","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}